New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2013
09:10 EDTELGXEndologix presents data from PEVAR randomized trial
Endologix announced that data from the first prospective, multicenter, randomized clinical trial of a totally percutaneous approach, or PEVAR, to endovascular abdominal aortic aneurysm repair, or EVAR, was recently presented at two medical meetings. Key points from the trial include the primary trial endpoint was met, definitively demonstrating the non-inferiority of PEVAR using the ProGlide closure device to surgical EVAR, a 94% procedural technical success rate was achieved in a multicenter setting, mean procedure time was reduced in PEVAR patients by 34 minutes. Likewise, mean time to hemostasis was reduced following PEVAR by 13 minutes, PEVAR patients required significantly fewer concomitant procedures, favorable trending of PEVAR in several clinical utility outcomes including reduced anesthesia time, reduced blood loss and need for transfusion, shorter hospital length of stay, and less analgesics prescribed for groin pain, and the PEVAR non-inferiority to surgical EVAR persisted through the final 6-month follow-up.
News For ELGX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2015
08:45 EDTELGXEndologix to present 'positive' Nellix clinical data at VEITH Symposium
Subscribe for More Information
07:32 EDTELGXCanaccord to hold a forum
Subscribe for More Information
November 18, 2015
16:04 EDTELGXEndologix, TriVascular announce early termination of HSR waiting period
Subscribe for More Information
10:01 EDTELGXEndologix to host investor meeting
Investor meeting to be held in New York on November 19 at 6 pm. Webcast Link
07:41 EDTELGXEndologix announces start of physician-initiated registry of Nellix EVAS System
Endologix announced the start of a physician-initiated registry of the Nellix EndoVascular Aneurysm Sealing System, or Nellix EVAS System, used with aortic branch stent grafts for the treatment of patients with complex abdominal aortic aneurysms, or AAAs. The registry, to be conducted outside of the United States, will be called the ASCEND Registry. The primary investigators are Andrew Holden, MD, Associate Professor of Radiology at Auckland Hospital; and Professor Matthew Thompson, MD, Professor of Vascular Surgery, St. Georges Vascular Institute, London. The Nellix System received CE Mark in 2013 for the treatment of patients with infrarenal AAAs. The Nellix System is an investigational device in the United States.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use